Some of the leading drug developers are already carrying out an optimized developability assessment and are mitigating many of the challenges faced in later stages of development. Poor expression, misfolding or aggregation can cause significant delays in moving molecules forward into the manufacturing stage of development. These problems are frequently avoidable for the sake of relatively little investment early in the drug development process.
Developability of Biopharmaceuticals has been designed to support drug developers in reducing the cost, risk and time of development. The agenda focuses on engineering developability in early drug development to ‘design in’ desirable manufacturing properties, together with addressing safety and efficacy in early drug development to minimize costly attrition..
Developability of Biopharmaceuticals is the world’s only meeting dedicated to integrating developability early in drug development. Meet and network with Directors, Associate Directors, Senior Scientists and Formulation experts to ensure maximum quality of discussions and add valuable contacts to your network
This means it is for:
“Very valuable and useful information. One of the best meetings I‟ve ever attended.” Millennium
“Strong program, great speakers and a genuine focus on identifying solutions” Novartis
“Fantastic program and good atmosphere” Novo Nordisk
“It exceeded my expectations. The talks were high quality and the interaction among participants was excellent” Genentech
“Great networking and a very good conference” Biogen Idec